This will enable cutting-edge life sciences research and support the discovery and development of novel biomarkers, diagnostics as well as personalised medicine applications.
Sapien plans to collaborate with healthcare enterprises and drug discovery companies globally to study disease epidemiology, validate new diagnostics, identify new drug targets and evaluate new drugs.
Sapien has exclusive access to the entire Apollo network for its bio-banking needs but expects to partner with additional research-oriented hospitals and clinics for their personalised medicine and bio-banking needs, the company said in a statement.
Sapien has entered into an alliance with Apollo Hospitals that allows Sapien to front-end Apollo's personalised medicine initiatives. This allows Sapien to bring novel cutting-edge diagnostics to Apollo, either on its own or in collaboration with best-of-breed institutions world-wide thereby enabling world-class healthcare and improving patient outcomes.
Speaking on the occasion, Shobana Kamineni, Executive Director, New Initiatives, Apollo Hospitals, said, "This is a proud moment for us at Apollo to be a part of this landmark initiative in the history of Indian Health care. Apollo Hospitals has long had a vision of creating Asia's largest bio-bank which is being realized in partnership with Saarum Innovations. Sapien will help fulfill our vision of delivering better clinical outcomes through bench-to-bedside innovation. This alliance is a further validation of Apollo's commitment to research-driven health care."
Speaking on the occasion Sreevatsa Natarajan, Co-founder and CEO, Sapien Biosciences said "Saarum Innovations is proud to be associated with a healthcare pioneer and leader like Apollo Hospitals. Apollo's passion for world-class healthcare combined with Saarum Innovations' proven research expertise will bridge healthcare and life-sciences and enable cutting-edge research and diagnostics applications."
Speaking on the occasion, Seemant Jauhari, CEO of AHERF said, "Apollo, through the Apollo Health Education and Research Foundation (AHERF), is spearheading a vibrant portfolio of innovative projects that will enable effective and affordable technologies for better treatment outcomes. Bio-banking and personalised medicine was one such initiative which is being realized with the launch of Sapien Biosciences."
Sapien Biosciences also announced the launch of its first and novel personalised medicine test, which determines patients' response to their blood-thinning medication and supports decision-making by their cardiologists to personalize therapy for better outcomes, the company said.
This the only test in India that combines both genetic and platelet function response to enable tailored anti-platelet therapy for each patient, it said.
Speaking on the occasion, Jugnu Jain, Co-founder and CSO, Sapien Biosciences said "Sapien's novel test offers more complete assessment of a patient's platelet response than existing tests and enables informed clinical decision-making thus exemplifying Sapien's approach to personalized medicine innovation."
Sapien Biosciences is managed by the Saarum Innovations team with Sreevatsa Natarajan as the Co-founder and CEO, Jugnu Jain as the Co-Founder and CSO, and Prithi Rajan as the Co-Founder and Executive Director.
--IBNS (Posted on 24-09-2013)